ClinVar Miner

Submissions for variant NM_000518.4(HBB):c.126_129delCTTT (p.Phe42fs) (rs80356821)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 9
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Center for Pediatric Genomic Medicine,Children's Mercy Hospital and Clinics RCV000508554 SCV000610030 pathogenic not provided 2017-03-22 criteria provided, single submitter clinical testing
Counsyl RCV000020328 SCV000678184 pathogenic beta Thalassemia 2015-11-24 criteria provided, single submitter clinical testing p.F42Lfs*19 is classified as a beta-zero mutation.
GeneDx RCV000508554 SCV000748427 pathogenic not provided 2018-03-06 criteria provided, single submitter clinical testing The c.126_129delCTTT variant in the HBB gene has been reported previously in the homozygous state or with a second HBB variant in multiple individuals with beta-thalassemia (Laosombat et al., 2001; Chen et. al 2010). The c.126_129delCTTT variant causes a frameshift starting with codon Phenylalanine 42, changes this amino acid to a Leucine residue, and creates a premature Stop codon at position 19 of the new reading frame, denoted p.Phe42LeufsX19. This variant is predicted to cause loss of normal protein function either through protein truncation or nonsense-mediated mRNA decay. The c.126_129delCTTT variant is observed in 38/18,850 (0.202%) alleles from individuals of East Asian background in large population cohorts (Lek et al., 2016). We interpret c.126_129delCTTT as a pathogenic variant.
GeneReviews RCV000020328 SCV000040704 pathogenic beta Thalassemia 2015-05-14 no assertion criteria provided literature only
Illumina Clinical Services Laboratory,Illumina RCV000020328 SCV000914517 likely pathogenic beta Thalassemia 2018-10-31 criteria provided, single submitter clinical testing The HBB c.126_129delCTTT (p.Phe42LeufsTer19) variant, also described as codon 41/42 (-CTTT) or codon 41/42 (-TTCT), results in a frameshift and is predicted to result in premature truncation of the protein. This variant is particularly prevalent in the Chinese population and is usually associated with a beta-thalassemia phenotype (Lin et al. 2014; Zhang et al. 2015; Yu et al. 2015; Origa et al 2015). Across a selection of the available literature, the p.Phe42LeufsTer19 variant has been identified in a homozygous state in one individual and in a compound heterozygous state in seven individuals, all with beta-thalassemia (Kimura et al. 1983; Hernanda et al. 2012; Huang et al. 2014; Italia et al. 2015; Rujito et al. 2015). Control data are unavailable for this variant, which is reported at a frequency of 0.00496 in the East Asian population of the 1000 Genomes. Based on the evidence and the potential impact of frameshift variants, the p.Phe42LeufsTer19 variant is interpreted as pathogenic for beta-thalassemia. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population.
Integrated Genetics/Laboratory Corporation of America RCV000020328 SCV000697076 pathogenic beta Thalassemia 2016-04-12 criteria provided, single submitter clinical testing Variant summary: The c.126_129delCTTT variant results in a premature termination codon, predicted to cause a truncated or absent HBB protein, which is a commonly known mechanism for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory (e.g.c.135delC, c.143_146dupATCT). Mutation taster predicts damaging outcome for this variant. This variant is found in 33/121370 control chromosomes at a frequency of 0.0002719, which does not exceed maximal expected frequency of a pathogenic allele (0.0111803). This variant is reported in the literatures as a well-known pathogenic variant predominantly identified in East and South Asian. In addition, multiple reputable databases classified this variant as pathogenic. Taken together, this variant was classified as pathogenic.
Invitae RCV000508554 SCV000956689 pathogenic not provided 2018-09-11 criteria provided, single submitter clinical testing This sequence change creates a premature translational stop signal (p.Phe42Leufs*19) in the HBB gene. It is expected to result in an absent or disrupted protein product. This variant is present in population databases (rs281864900, ExAC 0.2%). This variant has been observed in the homozygous and compound heterozygous state in several individuals with HBB-related conditions (PMID: 6826539, 28635337, 25089872). ClinVar contains an entry for this variant (Variation ID: 15417). Loss-of-function variants in HBB are known to be pathogenic (PMID: 7510147, 19269866, 23637309). For these reasons, this variant has been classified as Pathogenic.
OMIM RCV000016673 SCV000036943 pathogenic beta^0^ Thalassemia 2002-09-28 no assertion criteria provided literature only
Quest Diagnostics Nichols Institute San Juan Capistrano RCV000508554 SCV000601240 pathogenic not provided 2016-11-04 criteria provided, single submitter clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.